COGENT BIOSCIENCES INC (COGT) Stock Price, Quote, News and Overview
NASDAQ:COGT - Nasdaq - US19240Q2012 - Common Stock
COGT Quote and Key Statistics
COGENT BIOSCIENCES INC
NASDAQ:COGT (1/22/2025, 10:21:10 AM)
8.27
+0.07 (+0.85%)
COGT Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -63.1% | ||
| ROE | -77% | ||
| Debt/Equity | 0 |
COGT Performance and Technical Analysis
COGT Ownership and Analysts
COGT Latest News and Analysis
Wednesday 1/15 Insider Buying Report: COGT, GBIO
Noteworthy Tuesday Option Activity: COGT, LVS, MMM
Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. and BOULDER, Colo., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on...
Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket
Why Is Cogent Biosciences Stock Trading Higher On Monday?
On Sunday, Cogent Biosciences, Inc. (NASDAQ:COGT) revealed updated clinical results from the Open Label Extension (OLE) portion of the SUMMIT trial of bezuclastinib in patients with non-advanced systemic mastocytosis. Non-advanced systemic mastocytosis is a rare disease that involves mast cell buildup in tissues and organs. Updated clinical data presented at the American Society of Hematology Annual Meeting & Exposition show: 56% mean improvement in Total Symptom Score (TSS) at 24 weeks. 76% of
About COGT
Company Profile
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. The company is headquartered in Waltham, Massachusetts and currently employs 164 full-time employees. The company went IPO on 2018-03-29. The firm is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
Company Info
COGENT BIOSCIENCES INC
275 Wyman Street, 3rd Floor
Waltham MASSACHUSETTS 02140 US
CEO: Andrew Robbins
Employees: 164
Company Website: https://www.cogentbio.com/
Investor Relations: https://investors.cogentbio.com/
Phone: 16179455576
COGT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.78 | 299.83B | ||
| AMGN | AMGEN INC | 14.25 | 147.21B | ||
| GILD | GILEAD SCIENCES INC | 20.88 | 115.27B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 846.68 | 111.20B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.32 | 76.49B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.24B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.78B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.01B | ||
| NTRA | NATERA INC | N/A | 22.53B | ||
| BIIB | BIOGEN INC | 8.72 | 20.75B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.73B |